Arrakis Bio

Company Overview

Snapshot

Founded in March 2023 by Fabian Trumper and Maayan Gal, Arrakis Bio operates with 1–10 employees. The company has secured seed funding across one round from FLORA Ventures. In July 2023, Arrakis Bio received seed funding from FLORA Ventures.

Business overview

Arrakis Bio is a Health Tech & Life Sciences company focused on developing a breakthrough technology for the production of animal-free, high-quality, and pure human collagen and gelatin. The company's core technology aims to revolutionize the utilization of these materials, serving industries such as cosmetics and tissue regeneration. Arrakis Bio operates in the Pharma & Medical Biotechnology and Cosmetic Materials sectors, targeting the Healthcare & Life Sciences market.

Strategic signal

In July 2023, Arrakis Bio secured seed funding from FLORA Ventures. This investment signals early investor confidence in the company's innovative approach to producing animal-free collagen and gelatin, highlighting the growing market interest in sustainable and ethical alternatives within the life sciences and cosmetics industries.

Company Intelligence Q&A

When was Arrakis Bio founded?

Arrakis Bio was founded in March 2023.

Who are the founders of Arrakis Bio?

Arrakis Bio was founded by Fabian Trumper and Maayan Gal.

What is Arrakis Bio's primary focus?

Arrakis Bio is developing technology for the animal-free production of human collagen and gelatin, targeting applications in cosmetics and tissue regeneration.

Which investor participated in Arrakis Bio's seed funding round?

In July 2023, Arrakis Bio received seed funding from FLORA Ventures.

What sector does Arrakis Bio operate in?

Arrakis Bio operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Cosmetic Materials.